1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Slovakia Pharmaceuticals and Healthcare Report Q1 2017

Slovakia Pharmaceuticals and Healthcare Report Q1 2017

  • November 2016
  • -
  • Business Monitor International
  • -
  • 91 pages

Includes 3 FREE quarterly updates


BMI View:

Slovakia’s pharmaceutical market represents an opportunity for revenue growth for multinational drugmakers. The advanced regulatory environment will enable robust growth within the patented medicines market and the country will remain amongst the most attractive markets in the CEE region. However, growth will lag behind the less developed former soviet states as well as neighbouring Visegrad countries and the financial mismanagement of the healthcare system will continue to pose risks.

Headline Expenditure Projections



- Pharmaceuticals: EUR1.91bn (USD2.12bn) in 2015 to EUR1.98bn (USD2.12bn) in 2016; +3.6% in local currency terms and flat in US dollar terms. Forecast slightly increased in local currency terms from last quarter.

- Healthcare: EUR6.14bn (USD6.80bn) in 2015 to EUR6.36bn (USD6.81bn) in 2016; +3.7% in local currency terms and flat in US dollar terms. Forecast revised slightly downwards from last quarter.

Table Of Contents

Slovakia Pharmaceuticals and Healthcare Report Q1 2017
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Slovakia 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Slovakia 2012-2020) 13
Healthcare Market Forecast 13
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Slovakia 2012-2020) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Slovakia 2012-2020) 17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Slovakia 2012-2020) 17
Prescription Drug Market Forecast 18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Slovakia 2012-2020) 20
Patented Drug Market Forecast 21
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Slovakia 2012-2020) 22
Generic Drug Market Forecast 22
Table: Members Of GENAS, 2015 25
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Slovakia 2012-2020) 25
OTC Medicine Market Forecast 26
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Slovakia 2012-2020) 28
Pharmaceutical Trade Forecast 29
Table: Pharmaceutical Trade Data And Forecasts (Slovakia 2014-2020) 31
Table: Pharmaceutical Trade Data And Forecasts local currency (Slovakia 2014-2020) 31
Industry Risk/Reward Index 32
Central And Eastern Europe Risk/Reward Index 32
Slovakia Risk/Reward Index 39
Rewards 39
Risks 39
Regulatory Review 41
Regulatory Regime 41
Intellectual Property Issues 44
Pricing Regime 45
Table: Indexed Price Build-Up For Prescription And Non-Prescription Medicines In Slovakia 46
Reimbursement Regime 46
Market Overview 52
Table: Healthcare Resources (Slovakia 2010-2015) 55
Table: Healthcare Personnel (Slovakia 2010-2015) 55
Table: Healthcare Activity (Slovakia 2010-2015) 56
Research And Development 60
Table: Members Of BITCET, 2011 61
Table: Members Of SLOVBIOTECH, 2010 62
Clinical Trials 62
Epidemiology 63
Table: Main Causes Of Mortality And Morbidity In Slovakia 64
Competitive Landscape 66
Research-Based Industry 66
Table: Members Of SAFS, 2012 66
Table: Multinational Market Activity 67
Generic Drugmakers 68
Table: Registered Pharmaceutical Manufacturers 68
Pharmaceutical Distribution 69
Table: ADL Members, 2012 (Manufacturers, unless otherwise indicated) 70
Pharmaceutical Retail Sector 70
Company Profile 73
Biotika 73
HBM Pharma 75
Imuna Pharma 78
Demographic Forecast 80
Table: Population Headline Indicators (Slovakia 1990-2025) 81
Table: Key Population Ratios (Slovakia 1990-2025) 81
Table: Urban/Rural Population and Life Expectancy (Slovakia 1990-2025) 82
Table: Population By Age Group (Slovakia 1990-2025) 82
Table: Population By Age Group % (Slovakia 1990-2025) 83
Glossary 85
Methodology 87
Pharmaceutical Expenditure Forecast Model 87
Healthcare Expenditure Forecast Model 87
Notes On Methodology 88
Risk/Reward Index Methodology 89
Index Overview 90
Table: Pharmaceutical Risk/Reward Index Indicators 90
Indicator Weightings 91

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.